<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123399">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496131</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 63325-015</org_study_id>
    <secondary_id>BB-IND 7787</secondary_id>
    <nct_id>NCT01496131</nct_id>
  </id_info>
  <brief_title>Tecemotide (L-BLP25) in Prostate Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Enzyme-linked Immunosorbent Spot (ELISPOT) Level of Mucin-1 specific T-cells at 2 Months After Radiation</measure>
    <time_frame>Baseline (Day -16 to -1) and Week 27 (approximately 2 months after radiation)</time_frame>
    <description>To determine impact of tecemotide (L-BLP25) immunotherapy in addition to standard treatment on the mucinous glycoprotein 1 (MUC1) specific systemic immune response in subjects with untreated, intermediate and high risk prostate cancer tecemotide (L-BLP25) immunotherapy in combination with Androgen Deprivation Therapy (ADT) and radiation therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in the ELISPOT Level of Mucin-1 specific T-cells at 6 Months After Radiation</measure>
    <time_frame>Baseline (Day -16 to -1) and Week 40 (approximately 6 months after radiation)</time_frame>
    <description>To determine impact of tecemotide (L-BLP25) immunotherapy in addition to standard treatment on the MUC1 specific systemic immune response in subjects with untreated, intermediate and high risk prostate cancer tecemotide (L-BLP25) immunotherapy in combination with ADT and radiation therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates of Time to Disease Recurrence based on Prostate-specific antigen (PSA) Levels</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>To evaluate progression/recurrence status up to 24 months after randomization in subjects receiving tecemotide (L-BLP25) immunotherapy in combination with the standard treatment versus subjects receiving standard treatment alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects with a Doubling in Number of T-cells in tumor biopsy from Baseline to Week 27</measure>
    <time_frame>Baseline (Day -16 to -1) to Week 27</time_frame>
    <description>To analyze immunologic responses (in the tumor microenvironment) in subjects consenting to undergo study biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects with a Doubling of Number of T-cells in tumor biopsy from Baseline to Week 40</measure>
    <time_frame>Baseline (Day -16 to -1) to Week 40</time_frame>
    <description>To analyze immunologic responses (in the tumor microenvironment) in subjects consenting to undergo study biopsies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy in combination with androgen deprivation therapy (ADT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy plus tecemotide (L-BLP25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.</description>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_label>Standard therapy plus tecemotide (L-BLP25)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.</description>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_label>Standard therapy plus tecemotide (L-BLP25)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).</description>
    <arm_group_label>Standard therapy plus tecemotide (L-BLP25)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tecemotide (L-BLP25)</intervention_name>
    <description>Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.</description>
    <arm_group_label>Standard therapy plus tecemotide (L-BLP25)</arm_group_label>
    <other_name>L-BLP25</other_name>
    <other_name>BLP25 liposome vaccine</other_name>
    <other_name>Epipepimut-S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologic documentation of prostate cancer confirmed at the institution of
             study enrollment prior to starting this study

          -  Newly diagnosed or previously untreated prostate cancer with intermediate or high
             risk features as defined in the protocol

          -  No evidence of metastatic disease on computed tomography (CT) / magnetic resonance
             imaging (MRI) or bone scans

          -  No systemic steroid use within 2 weeks prior to initiation of experimental therapy.
             Limited doses of systemic steroids to prevent intravenous contrast, allergic reaction
             or anaphylaxis (in subjects who have known contrast allergies) are allowed

          -  Eastern Co-operative Oncology Group (ECOG) performance status of 0-1

          -  Human leukocyte antigen (HLA)-A2 or A3 positive for immunologic monitoring

          -  Hematological and biochemical eligibility parameters as defined in the protocol

          -  No other active malignancies within the past 3 years (with the exception of
             non-melanoma skin cancers or carcinoma in situ of the bladder)

          -  Willing to travel to the study center(s) for follow-up visits

          -  Age greater than or equal to 18 years old

          -  Able to understand and sign informed consent

          -  Must agree to use effective birth control (such as a condom) or abstinence during and
             for a period of 4 months after the last administration of immunotherapy

        Exclusion Criteria:

          -  No evidence of being immunocompromised by human immunodeficiency virus, a medical
             condition requiring systemic steroids, a medical condition requiring
             immunosuppressive therapy, splenectomy

          -  Active Hepatitis B or Hepatitis C

          -  Subjects should have no autoimmune diseases that have required treatment as specified
             in the protocol

          -  History of immunodeficiency diseases, hereditary or congenital immunodeficiencies

          -  Serious intercurrent medical illness

          -  A clinically significant cardiac disease

          -  Subjects who have received any prior therapy for prostate cancer

          -  Subjects who have known brain metastasis, or with a history of seizures,
             encephalitis, or multiple sclerosis

          -  Subjects receiving any other investigational agents

          -  Contraindication to biopsy such as bleeding disorders, ratio of prothrombin time to
             partial thromboplastin time (PT/PTT) &gt;=1.5 times the upper limit of normal,
             artificial heart valve

          -  Contraindication to MRI such as subjects weighing &gt;136 kilograms, allergy to magnetic
             resonance (MR) contrast agent, subjects with pacemakers, cerebral aneurysm clips,
             shrapnel injury or implantable electronic devices

          -  Contraindication to radiation therapy such as pre-existing and active prostatitis or
             proctitis, inflammatory bowel disease or known genetic sensitivity to ionizing
             radiation, or history of prior radiation to the pelvis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono, an affiliate of MerckKGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please Contact US Medical Information</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>November 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tecemotide</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Goserelin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
